jrnls.org logo
Submit

BROWSE ALL JOURNALS

Type 2 letters to search all 19 journals

SEE ALL 19 JOURNALS
Journal of Pharmacology and PharmacotherapeuticsNOW IN
Back

JPP · Lens · EGFR Isoforms Might be Responsible for the Diminished Treatment Outcome of EGFR Inhibitors

PDF

Communication · Volume 17, Issue 1 · pp. 145–147

EGFR Isoforms Might be Responsible for the Diminished Treatment Outcome of EGFR Inhibitors

Rajdeep Chakraborty1,2, Pallavi Khodlan1, Arthur Chien3, Chao Shen3, Thiri Zaw4, Matthew Fitzhenry4, Ardeshir Amirkhani4, Fei Liu2

  1. 1Applied Biosciences, Faculty of Science and Engineering, Macquarie University, Sydney, NSW, AUSTRALIA.
  2. 2School of Natural Sciences, Faculty of Science and Engineering, Macquarie University, Sydney, NSW, AUSTRALIA.
  3. 3Macquarie Analytical & Fabrication Facility, Faculty of Science and Engineering, Macquarie University, Sydney, NSW, AUSTRALIA.
  4. 4Australian Proteome Analysis Facility, Faculty of Science and Engineering, Macquarie University, Sydney, NSW, AUSTRALIA.

Abstract

Epidermal growth factor receptor (EGFR) plays an active role during the progression of oral squamous cell carcinoma (OSCC). OSCC is the most common head and neck cancer. Cetuximab, which is an inhibitor of EGFR, was approved by the Food and Drug Administration (FDA) in 2006 for the treatment of head and neck cancer. After initial clinical success, Cetuximab proved to be ineffective in the management of aggressive or metastatic oral cancer lesions. We hypothesize that EGFR has multiple isoforms that lead to the failure of Cetuximab. A future study of EGFR isoforms and protein-interacting partners will address the issue.

Keywords: Anti-tumor reactivity; Cetuximab; epidermal growth factor receptor; oral cancer

The full text of this article is available as a PDF. Open the PDF.